6505-99-3
6505-99-3
Chemical Structure
JA2131
- No. CAS: 6505-99-3
- Formula:C13H19N5O2S2
- Molecular Weight:341.45
IUPAC Name: 1,3-dimethyl-8-((2-morpholinoethyl)thio)-6-thioxo-1,3,6,9-tetrahydro-2H-purin-2-one
InChIKey: XHNSOGDMSSHQFY-UHFFFAOYSA-N
SMILES: O=C(N1C)N(C)C2=C(N=C(SCCN3CCOCC3)N2)C1=S
Biological Activity: JA2131 is a small molecular inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG) (IC50=0.4 μM). JA2131 regulate DNA damage responses, causes replication fork stalling and cancer cell death[1][2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JA2131 | 99.7% | JA2131 is a small molecular inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG) (IC50=0.4 μM). JA2131 regulate DNA damage responses, causes replication fork stalling and cancer cell death. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Theophylline (sodium glycinate) | Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-2286 | L-2286 is an orally active PARP-1 inhibitor. L-2286 alleviates carotid artery remodeling, oxidative stress and inflammation in spontaneously hypertensive rats, protects neurons in the dorsal hippocampus, and reduces pyramidal cell loss and gliosis without affecting blood pressure. L-2286 can be used in research related to hypertension. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
TPBM | 98.51% | TPBM is a potent estrogen receptor α (ERα) inhibitor with an IC50 value of 9 μM for 17β-estradiol (E2)-ERα. TPBM reduces E2·ERα recruitment to an endogenous estrogen-responsive gene. TPBM inhibits E2-dependent growth of ERα-positive cancer cells (IC50=5 μM). TPBM is not toxic to cells and does not affect estrogen-independent cell growth. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ANAT inhibitor-1 | ANAT inhibitor-1 is a human aspartate N-acetyltransferase (ANAT) inhibitor for canavan disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fabomotizole | 99.96% | Fabomotizole (CM346) is an insecticide with anxiolytic, antianxiety, and neuroprotective activities and a substrate of p-glycoprotein. Fabomotizole inhibits the ST-segment depression induced by isoproterenol in a rat model of acute subendocardial ischemia. Fabomotizole also inhibits Giardia lamblia and has the potential to inhibit giardiasis. Fabomotizole also targets Sigma1R, NRH:quinone reductase 2 (NQO2), and MAO-A to exert anxiolytic effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fabomotizole hydrochloride (Standard) | ≥98% | Fabomotizole (hydrochloride) (Standard) is the analytical standard of Fabomotizole (hydrochloride). This product is intended for research and analytical applications. Fabomotizole (CM346) hydrochloride is a compound with anxiolytic and neuroprotective activities. Fabomotizole (CM346) hydrochloride also has activity against Giardia lamblia and has the potential to inhibit giardiasis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fabomotizole dihydrochloride | Fabomotizole dihydrochloride is an anxiolytic agent. Fabomotizole dihydrochloride produces anxiolytic and neuroprotective effects without any muscle relaxant actions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pamabrom | 99.92% | Pamabrom is a diuretic that acts on the opioid receptor-nitric oxide (NO) -cyclic guanosine monophosphate (cGMP) -K+ channel pathway. Pamabrom exerts peripheral antinociceptive activity by activating this pathway. The mechanism involves activating opioid receptors, promoting the release of nitric oxide, and then influencing cyclic guanosine monophosphate and K channels to produce an analgesic effect. Pamabrom is orally active and is mainly used in the research and treatment of premenstrual syndrome and primary dysmenorrhea |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Doxofylline | 99.97% | Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Cyclopentyl-1,3-dimethylxanthine | 99.83% | 8-Cyclopentyl-1,3-dimethylxanthine (Compound 2a) is a selective adenosine A1 receptor antagonist with Kis of 10.9 nM and 1440 nM for A1 receptor and A2 receptor, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Houl JH, et al. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat Commun. 2019 Dec 11;10(1):5654. [Content Brief]
- [2]. Brosey CA, et al. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors. Prog Biophys Mol Biol. 2021 Aug;163:171-186. [Content Brief]
